2022
Digoxin as an emerging therapy in noncardiac diseases
Dashti F, Jamshed F, Ouyang X, Mehal W, Banini B. Digoxin as an emerging therapy in noncardiac diseases. Trends In Pharmacological Sciences 2022, 44: 199-203. PMID: 36396496, DOI: 10.1016/j.tips.2022.10.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2015
Antifibrotic Therapies in the Liver
Mehal W, Schuppan D. Antifibrotic Therapies in the Liver. Seminars In Liver Disease 2015, 35: 184-198. PMID: 25974903, PMCID: PMC5743222, DOI: 10.1055/s-0035-1550055.Peer-Reviewed Original ResearchConceptsAntifibrotic therapyIdeal patient populationRegression of fibrosisBest noninvasive methodFibrolytic propertiesDose titrationClinical outcomesFibrosis regressionPulmonary fibrosisPatient populationCombination therapyLiver fibrosisIndividualized therapyEncouraging dataFibrotic responseTherapeutic targetDrug AdministrationFibrosisTherapyNoninvasive methodInterindividual heterogeneityCell populationsAntifibroticsLiverFibrolysis